Search research articles
Contact Us
Filters
Showing results (131-140 of 139) with videos related to
Page
of 14
Sort By:
You have reached the last page of results.
This site can display upto 139 results.
British Journal of Haematology
|
May 3, 2000
Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice
T Lamy, F A Bauer, J H Liu, et al.
Leukemia
|
June 5, 2014
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2
S Manni, D Toscani, E Mandato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2014
Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients
E Poullot, R Zambello, F Leblanc, et al.
Leukemia
|
November 28, 2013
Cyclophosphamide as a first-line therapy in LGL leukemia
A Moignet, Z Hasanali, R Zambello, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 2, 1998
Involvement of the IP-10 chemokine in sarcoid granulomatous reactions
C Agostini, M Cassatella, R Zambello, et al.
Clinical Radiology
|
June 8, 2017
Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma
C Lacognata, F Crimì, A Guolo, et al.
Leukemia
|
August 2, 2016
Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia
L Quotti Tubi, S Canovas Nunes, A Brancalion, et al.
Clinical and Experimental Medicine
|
November 25, 2025
A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide
I Rizzello, I Sacchetti, S Barbato, et al.
ESMO Open
|
January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
E A Martino, S Palmieri, M Galli, et al.
Page
of 14
Search research articles
Search
Showing results (131-140 of 139) with videos related to
Sort By:
Page
of 14
You have reached the last page of results.
This site can display upto 139 results.
British Journal of Haematology
|
May 3, 2000
Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice
T Lamy, F A Bauer, J H Liu, et al.
Leukemia
|
June 5, 2014
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2
S Manni, D Toscani, E Mandato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2014
Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients
E Poullot, R Zambello, F Leblanc, et al.
Leukemia
|
November 28, 2013
Cyclophosphamide as a first-line therapy in LGL leukemia
A Moignet, Z Hasanali, R Zambello, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 2, 1998
Involvement of the IP-10 chemokine in sarcoid granulomatous reactions
C Agostini, M Cassatella, R Zambello, et al.
Clinical Radiology
|
June 8, 2017
Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma
C Lacognata, F Crimì, A Guolo, et al.
Leukemia
|
August 2, 2016
Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia
L Quotti Tubi, S Canovas Nunes, A Brancalion, et al.
Clinical and Experimental Medicine
|
November 25, 2025
A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide
I Rizzello, I Sacchetti, S Barbato, et al.
ESMO Open
|
January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
E A Martino, S Palmieri, M Galli, et al.
Page
of 14